efzofitimod
·Code: KRP-R120
efzofitimod: developed by 1 company · 1 clinical trial tracked.
efzofitimod evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect efzofitimod to ATYR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could efzofitimod → ATYR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Pulmonary Sarcoidosis
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| aTYR PHARMA INC (ATYR) Pulmonary Sarcoidosis | Phase 3 |
Clinical Trials (1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Primary endpoint: Change from baseline in mean daily oral corticosteroid (OCS) dose at Week 48
InterventionalRandomizedquadruple268 enrolledStarted 2022-09Completion 2025-0750 sites · Brazil, France, Germany, United StatesaTyr Pharma, Inc.
Frequently asked questions
Who is developing efzofitimod?
efzofitimod is being developed by aTYR PHARMA INC.
How many clinical trials involve efzofitimod?
BioSniper tracks 1 clinical trial involving efzofitimod.